0
0

Affordable Drug Manufacturing Act of 2019

10/28/2022, 1:46 AM

Congressional Summary of HR 5501

Affordable Drug Manufacturing Act of 2019

This bill establishes the Office of Drug Manufacturing within the Department of Health and Human Services to lower prices for, increase access to, and address shortages of prescription drugs (e.g., insulin, naloxone, and antibiotics), including by manufacturing prescription drugs and selling them at a fair price.

Current Status of Bill HR 5501

Bill HR 5501 is currently in the status of Bill Introduced since December 19, 2019. Bill HR 5501 was introduced during Congress 116 and was introduced to the House on December 19, 2019.  Bill HR 5501's most recent activity was Referred to the Subcommittee on Health. as of December 20, 2019

Bipartisan Support of Bill HR 5501

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
0
Democrat Cosponsors
0
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 5501

Primary Policy Focus

Health

Potential Impact Areas

- Competition and antitrust
- Congressional oversight
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Executive agency funding and structure
- Federal officials
- Government employee pay, benefits, personnel management
- Health care costs and insurance
- Health care coverage and access
- Health care quality
- Health programs administration and funding
- Inflation and prices
- Licensing and registrations
- Manufacturing
- Prescription drugs
- Public contracts and procurement
- Public participation and lobbying

Alternate Title(s) of Bill HR 5501

Affordable Drug Manufacturing Act of 2019
To amend the Public Health Service Act to establish an Office of Drug Manufacturing.
Affordable Drug Manufacturing Act of 2019

Comments